In brief
In a significant move aimed at curbing prescription drug costs for seniors, the Medicare program has revealed a list of 15 new drugs eligible for price negotiations. This initiative, part of the Trump administration's efforts to tackle exorbitant medication prices, could lead to substantial savings starting in 2028. The selected medications treat various health conditions, underscoring a commitment to supporting older Americans amidst rising healthcare expenses.
NEW YORK (AP) — The Centers for Medicare and Medicaid Services (CMS) has announced a fresh list of 15 medications selected for price negotiations aimed at lowering costs for seniors enrolled in Medicare. This initiative allows the federal government to negotiate directly with drug manufacturers, a strategy intended to minimize the burden of high prescription drug prices on older Americans and taxpayers.
Among the drugs identified are widely used treatments for Type 2 diabetes, such as Trulicity, as well as medications for HIV and arthritis, indicating a broad impact on various health conditions affecting senior citizens. The negotiations are projected to yield substantial savings once implemented in 2028, following the schedule mandated by the 2022 law enabling such discussions.
“For too long, seniors and taxpayers have paid the price for skyrocketing prescription drug costs,” said Dr. Mehmet Oz, Administrator of the CMS. “Under the leadership of President Trump, CMS is taking strong action to address this issue by negotiating fair prices on the most costly drugs in Medicare.”
The timeline requires the government to finalize its list of drugs by February 1. This year’s negotiations mark the third round of the program, increasing the total number of drugs with negotiated prices for Medicare enrollees to 40. Previous negotiations have included highly utilized GLP-1 diabetes drugs such as Ozempic and Wegovy.
For the first time, drugs covered under Medicare Part B, typically outpatient prescriptions administered at healthcare facilities, are eligible for negotiation. The newly selected medications also include Botox, commonly used for various medical treatments, although pricing will focus on its Medicare-approved applications.
According to CMS, approximately 1.8 million Medicare Part B and Part D enrollees utilized the 15 drugs last year, which represented around 6% of total Part B and Part D expenditures. In a related development, AARP CEO Dr. Myechia Minter-Jordan commended the announcement as a significant advancement in the fight for affordable medications for older Americans.
However, the pharmaceutical industry has expressed concerns regarding the price negotiation law, suggesting that a more effective approach would involve addressing insurance costs and the roles of pharmacy benefit managers. The newly added drugs up for negotiation include notable names like Biktarvy, Botox, and various medications for chronic conditions such as psoriasis and depression.
As healthcare costs continue to rise, this initiative reflects ongoing efforts to ensure that Medicare functions effectively for patients rather than serving privileged interests in the pharmaceutical sector.
